logo-loader

RadiSys joins CORD data center project

Last updated: 11:56 15 Mar 2016 EDT, First published: 07:56 15 Mar 2016 EDT

server-room
CORD is targeted at telecommunications companies

Media content software company RadiSys Corporation (NASDAQ:RSYS) has become one of the leading systems integrators for cloud-based data center system CORD.

CORD, or to give it its cumbersome full name, the Central Office Re-architected as a Datacenter, offers an open service delivery platform that has been described as network infrastructure-as-a-service.

Targeted at telecommunications, it allows service providers to build an underlying common infrastructure with white-label boxes that are not necessarily located in a single central location.

Radisys’s implementation of CORD combines a deployable hardware blueprint together with a complete open source software stack and a suite of professional services to enable operators to quickly and easily leverage the benefits of commodity building blocks in their central office transformation projects.

Radisys said it will help service providers and the community turn residential, enterprise and mobile CORD proofs-of-concept into deployable carrier-grade solutions by offering “end-to-end world class support” for CORD integration and commercial deployment on Radisys’s DCEngine hyper-scale data center product.

“The vendor community is critical to helping service providers evolve their central offices as they seek to move services to the edge of the network using SDN [software defined network] and NFV [network functionalization] technologies, prepare for 5G and improve agility and enhance the overall subscriber experience,” said Guru Parulkar, co-founder and executive director of the Open Networking Lab (ON.Lab) and also board chairman of ONOS, the open source SDN networking operating system.

“Radisys’s deep and proven expertise in SDN, open hardware and complex telecommunication software systems make them an ideal integrator for CORD. We are very pleased to have them stepping into this critical role,” he said.

Shares rose 3.9% to $3.72.

 

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

8 minutes ago